Insider · CIK 0001810882

Lebwohl David

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001810882

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-01	NTLAIntellia Therapeutics, Inc.A Award	EVP, Chief Medical Officer	AAward	+9,943 sh	—	—	131,192
2026-03-01	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Medical Officer	AAward	+14.2K sh	—	—	14,204
2026-01-05	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−11.9K sh	$9.21	−$110K	121,249
2025-03-01	NTLAIntellia Therapeutics, Inc.A Award	EVP, Chief Medical Officer	AAward	+43.2K sh	—	—	130,866
2025-03-01	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Medical Officer	AAward	+61.7K sh	—	—	61,714
2025-01-03	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−9,557 sh	$12.18	−$116K	87,666
2025-01-01	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+3,189 sh	—	—	97,223
2025-01-01	NTLAIntellia Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−3,189 sh	—	—	0
2024-03-01	NTLAIntellia Therapeutics, Inc.A Award	EVP, Chief Medical Officer	AAward	+38.7K sh	—	—	93,073
2024-03-01	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Medical Officer	AAward	+55.9K sh	—	—	55,855
2024-01-03	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−5,843 sh	$29.46	−$172K	54,372
2024-01-01	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+3,187 sh	—	—	60,215
2024-01-01	NTLAIntellia Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−3,187 sh	—	—	3,189
2023-03-01	NTLAIntellia Therapeutics, Inc.A Award	EVP, Chief Medical Officer	AAward	+30.7K sh	—	—	56,361
2023-03-01	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Medical Officer	AAward	+43.3K sh	—	—	43,342
2023-01-04	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−2,574 sh	$37.21	−$95.8K	25,687
2023-01-01	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+3,187 sh	—	—	28,261
2023-01-01	NTLAIntellia Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−3,187 sh	—	—	6,376
2022-03-01	NTLAIntellia Therapeutics, Inc.A Award	EVP, Chief Medical Officer	AAward	+13.8K sh	—	—	24,738
2022-03-01	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Medical Officer	AAward	+13.8K sh	—	—	13,816
2022-03-01	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Medical Officer	AAward	+20.2K sh	—	—	20,203
2022-01-01	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+3,187 sh	—	—	11,973
2022-01-01	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−1,051 sh	$112.24	−$118K	10,922
2022-01-01	NTLAIntellia Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−3,187 sh	—	—	9,563
2021-11-05	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+2,400 sh	$12.62	+$30.3K	11,114
2021-11-05	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−1,200 sh	$131.71	−$158K	9,914
2021-11-05	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−452 sh	$132.62	−$59.9K	9,462
2021-11-05	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−548 sh	$134.07	−$73.5K	8,914
2021-11-05	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−200 sh	$135.34	−$27.1K	8,714
2021-11-05	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−2,400 sh	—	—	180,077
2021-10-14	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+2,400 sh	$12.62	+$30.3K	11,114
2021-10-14	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−551 sh	$126.92	−$69.9K	10,563
2021-10-14	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−849 sh	$127.81	−$109K	9,714
2021-10-14	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−225 sh	$129.01	−$29K	9,489
2021-10-14	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−525 sh	$129.83	−$68.2K	8,964
2021-10-14	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−250 sh	$130.47	−$32.6K	8,714
2021-10-14	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−2,400 sh	—	—	182,477
2021-09-24	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+7,923 sh	$12.62	+$100K	8,714
2021-09-24	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−7,923 sh	—	—	184,877
2021-09-21	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+2,400 sh	$12.62	+$30.3K	3,191
2021-09-21	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−2,400 sh	$149.81	−$360K	791
2021-09-21	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−2,400 sh	—	—	192,800
2021-08-30	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+2,400 sh	$12.62	+$30.3K	3,191
2021-08-30	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−200 sh	$155.43	−$31.1K	2,991
2021-08-30	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−700 sh	$156.70	−$110K	2,291
2021-08-30	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−250 sh	$157.60	−$39.4K	2,041
2021-08-30	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−1,100 sh	$159.19	−$175K	941
2021-08-30	NTLAIntellia Therapeutics, Inc.S Sale	EVP, Chief Medical Officer	SSale	−150 sh	$160.10	−$24K	791
2021-08-30	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	−2,400 sh	—	—	195,200
2021-08-09	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Medical Officer	MExercise/Conversion	+2,400 sh	$12.62	+$30.3K	3,191

Recent filings

Accepted (ET)
Mar 34
Lebwohl David0001193125-26-088258
SEC(opens sec.gov)
Jan 74
Lebwohl David0001193125-26-006283
SEC(opens sec.gov)
Mar 44
Lebwohl David0000950170-25-032125
SEC(opens sec.gov)
Jan 74
Lebwohl David0000950170-25-003015
SEC(opens sec.gov)
Jan 34
Lebwohl David0000950170-25-001237
SEC(opens sec.gov)
Mar 54
Lebwohl David0000950170-24-025904
SEC(opens sec.gov)
Jan 54
Lebwohl David0000950170-24-002515
SEC(opens sec.gov)
Jan 34
Lebwohl David0000950170-24-001204
SEC(opens sec.gov)
Mar 34
Lebwohl David0001209191-23-015753
SEC(opens sec.gov)
Jan 64
Lebwohl David0001209191-23-002417
SEC(opens sec.gov)
Jan 44
Lebwohl David0001209191-23-001492
SEC(opens sec.gov)
Mar 44/A
Lebwohl David0001209191-22-016533
SEC(opens sec.gov)
Mar 34
Lebwohl David0001209191-22-015960
SEC(opens sec.gov)

Companies

Intellia Therapeutics, Inc.EVP, Chief Medical OfficerNTLA

Address

C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130

CAMBRIDGE, MA, 02139